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Systematic Review and meta-analysis of evidence on the effect of early 
glycaemic control on HbA1c tracking and development of vascular 
complications after 5 years of childhood onset type 1 diabetes.  
 
ABSTRACT 
 
Objective: A systematic review and meta-analysis was conducted to investigate if 
glycaemic control measured by glycated Haemoglobin (HbA1c)  levels near diagnosis 
are predictive of future glycaemic outcomes in childhood onset type 1 diabetes (T1D). 
 
Methods: Evidence was searched through electronic databases (MEDLINE, 
EMBASE, Web of Science, CINAHL, Scopus and Cochrane Library up to February 
2017), grey literature, reference lists and correspondence with authors. Studies 
meeting the inclusion criteria were systematically double-reviewed, quality assessed 
and outcome data extracted for narrative synthesis and meta-analysis.  
 
Findings: Five studies (N=4227 participants) were eligible for this review and meta-
analysis. HbA1c levels were sub-optimal throughout the study period but tend to 
stabilise in a “track” by 6 months after T1D diagnosis. The group with low HbA1c 
<53mmol/mol (<7%) at baseline had lower long-term HbA1c levels than the higher 
HbA1c group but the estimated standardised mean difference between the sub groups 
was very small.  
 
Only one study investigated the association between early glycaemic control and 
development of vascular complications in childhood onset T1D and reported that 
children with higher HbA1c (≥ 8.7%; ≥70 mmol/mol) at 3- 15 months post diagnosis 
was associated with increased risk of developing albuminuria and retinopathy. 
 
Interpretations: Glycaemic control after the first few months of childhood onset T1D, 
remains stable but sub-optimal for a decade. Children with good early glycaemic 
control at baseline also appear to have good long-term glycaemic control compared 
to those with poor control at baseline. 
 
PROSPERO registration: CRD42015024546 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015024546 
  
INTRODUCTION 
Glycated haemoglobin A1c (HbA1c) levels, a measure for glycaemic control is the 
main predictor of long-term type 1 diabetes (T1D) outcomes, despite other 
confounders (1-3). HbA1c levels are highest at diagnosis, which improve after insulin 
treatment and remain stable in most T1D patients. However, a few find it challenging 
to maintain good glycaemic control despite targeted or intensive interventions, for a 
variety of reasons as they go through various stages in life (4, 5).  
 
Studies mainly in adults have shown a link between poor glycaemic control in the early 
phase following T1D diagnosis and long-term HbA1c levels, with an increased risk of 
developing vascular complications and mortality (6, 7). The risk of vascular 
complications is likely to be greater for childhood onset T1D, due to a longer duration 
of glycaemic exposure (8) and pathophysiological factors such as reduced insulin 
sensitivity and psychosocial behaviours such as insulin omission (9-11). For childhood 
onset T1D, some observational studies indicate an association between poor 
glycaemic control within one or two years of diagnosis and vascular complications in 
later life (12-14). Others suggest that mean HbA1c levels nearer to diagnosis are 
predictive of HbA1c levels in the subsequent years, even lifetime regardless of the 
type of insulin regimen (15-17).  This phenomenon, known as glycaemic “tracking” is 
poorly understood (18). It is unclear exactly when and in whom the phenomenon of 
“tracking” of HbA1c occurs in childhood onset T1D and if it is due to the natural history 
of T1D. It is therefore important to investigate evidence on this phenomenon in order 
to identify if there exists a window period during the initial phase of T1D diagnosis, 
during which appropriate resources could be mobilised to deliver targeted 
interventions to those at risk of developing poorer long-term glycaemic outcomes and 
vascular complications. 
 
The purpose of our study was to carry out a systematic review and meta-analysis of 
the evidence assessing the impact of early glycaemic control in children (followed for 
at least 5 years from diagnosis) on HbA1c tracking and the risk of developing vascular 
complications.  
 
METHODS 
This review is part of a series of systematic reviews of evidence on the effects of early 
glycaemic control in childhood onset T1D. The review protocol was registered in 
PROSPERO (Registration number: CRD42015024546) and a detailed protocol 
published (19). We followed the review methods for the rigorous conduct and reporting 
of systematic reviews for policy and practice as described by the Evidence for Policy 
and Practice Information (EPPI) Centre (20) which are as per PRISMA guidelines (21).  
 
Search strategy  
 
A refined search strategy was designed after a number of initial iterative scoping 
searches, with input from experts in the field to maximize capturing of key publications. 
Three sets of search terms were used relating to population (children and young 
people diagnosed with T1D), exposure (terms to capture observational, intervention, 
qualitative studies and review articles relating to early diabetes control) and outcome 
(complications, mortality, glycaemic tracking i.e. metabolic memory) (additional file 1).  
Six electronic databases: (MEDLINE and EMBASE via OVID, Web of Science via 
Thompson Reuters, CINAHL Plus via EBSCO, Scopus via Elsevier and the Cochrane 
Library), were double searched in parallel by HC & VMP from inception to December 
2014 and updated in February 2017 by using a combination of free text and Thesaurus 
or MeSH terms (additional file 2). No time-period or language restrictions were applied. 
All identified articles from electronic databases were imported into Endnote and de-
duplicated for further review. This was supplemented by hand-searching of reference 
lists of studies and reviews, grey literature, personal databases and contacting experts 
and authors of included studies for additional or unpublished data.  
 
Study selection 
Interventional and observational studies with a follow-up of ≥ 5 years from diagnosis 
of T1D which described and quantified the association between early glycaemic 
control (within 2 years of diagnosis of T1D) AND long-term glycaemic tracking and risk 
of future complications in children and young people aged 0 to 19 years at baseline 
were included (Additional file 3).  
 
In addition to running electronic database searches in parallel (HC and VMP), sub-
samples of papers were double-reviewed (DC and VMP), at each stage of the review 
process (title and abstract screening, data extraction and quality assessment). The 
interrater reliability for study selection was substantial (22). Full texts of abstracts 
appearing to meet the inclusion criteria were retrieved and their status was recorded 
in a pre-piloted excel spread sheet, which included specific study details and reasons 
for exclusion (for excluded studies). No foreign language papers were identified. 
Articles were re-examined (DC and VMP) if there was uncertainty about inclusion 
criteria and disagreements were resolved at team meetings. 
 
Data extraction and synthesis 
Data from included studies were extracted, analysed and synthesised by one reviewer 
(VMP). A proportion of shortlisted studies were also independently double reviewed 
and data extracted by another reviewer (DC & RA). From observational studies, data 
on HbA1c levels were extracted at all available time points from diagnosis. The data 
on HbA1c tracking and the association between early glycaemic control and chronic 
complications or markers of chronic complications at follow-up were extracted 
(additional file 4). Authors of included studies were contacted for clarity and additional 
information on HbA1c tracking data.  The main outcome of interest was tracking of 
early glycaemic control based on HbA1c measurements as percentage (DCCT) and/or 
mmol/mol (International Federation of Clinical Chemistry) units. The secondary 
outcome of interest was the effect of early glycaemic control on the development of 
micro and macro vascular complications during the long-term follow-up period. 
 
Quality assessment  
The quality of included studies was assessed independently by two reviewers (DC and 
VMP) using the quality assessment criteria by the EPPI Centre (20). Any 
disagreements were resolved by consensus. Scores were based on six items focusing 
on both internal and external validity (additional file 5). Observational studies were 
classified as high (≥5), intermediate (3-4) or low (≤2) quality based on the number of 
quality criteria met out of a maximum assessment score of six.  
 
Statistical analysis 
Information extracted from included studies were summarised through descriptive 
narrative synthesis and meta-analysis (23). All statistical analysis were conducted by 
one reviewer (VMP) and were verified by second reviewer (JB). The sample size, 
mean HbA1c measurements and standard deviation (SD) or standard error (SE) were 
available at population level and/or for categorised low and high HbA1c groups. Where 
not reported, the SE of the study effect size at each time point was calculated using 
the reported SD and the group sample sizes. Baseline period included 3-6 months 
from T1D diagnosis. Mean HbA1c levels at diagnosis was not included in the main 
meta-analysis as was prior to exposure to glycaemic control. The effect sizes and their 
SE were divided with SD to obtain standardised mean differences (SMD) (24).   
 
Heterogeneity between studies was expected and therefore both fixed effects (FE, 
inverse variance) and random effects (RE, Dersimonian and Laird) models were used 
to pool the effect sizes (25). The heterogeneity between studies was assessed using 
the χ2 and I2 statistics (26). The meta-analyses were carried using the metan command 
in STATA 15, StataCorp, College Station, Texas 77845 USA.    
 
Meta-analysis of studies combined overall changes in mean HbA1c. The low HbA1c 
(<7% at baseline) group was considered the treated/exposed group and the high 
HbA1c group (≥7% at baseline) was the control group. If multiple comparisons of 
HbA1c levels were reported in studies reported then these measures were combined 
within each study before meta-analysis. The changes in HbA1c levels between groups 
(low v/s high) at baseline (0-6 months of diagnosis), 1, 2, 3, 5, 7 and 10 year follow 
up, were estimated using inverse variance and DerSimonian and Laird and reported 
using forest plots.  
 
For glycated haemoglobin, the estimated pooled standardised effect size were 
converted into absolute units, to facilitate clinical interpretation, by multiplying the 
estimate by the pooled SD of all included studies of the meta-analysis. 
 
Furthermore, the long –term HbA1c trajectories between studies were compared with 
the overall estimate at all-time points of follow-up obtained from the meta-analysis.  
The HbA1c sub groups (low v/s high) were also compared across studies.  
 
The robustness of the meta-analysis to the choice of meta-analysis model was 
assessed by comparing FE and RE pooled standardised effect sizes. In a sensitivity 
analysis we excluded studies in pre-school children.   
 
Assessing publication bias using the funnel plots, the Begg’s rank correlation test or 
the Egger’s linear regression test was deemed inappropriate, as there were only five 
studies included in the review. 
 
Due to the small number of included studies, meta -regression was not appropriate to 
explore heterogeneity between studies or to investigate if there were other potential 
factors that could be independently associated with long-term glycaemic control. A 
minimum of 10 studies per study level parameter was needed in order to explore 
heterogeneity.  
 
Only one included study assessed the association of micro and macro vascular 
complications with early glycaemic control, which precluded a meta-analysis and 
results of which were narrated separately.  
 
RESULTS 
The literature search strategy on glycaemic control in childhood onset T1D identified 
articles from individual databases (Medline via OVID, n = 14,688; Embase via OVID, 
n = 843; Web of Science via Thompson Reuters, n = 2,734; CINAHL Plus via EBSCO, 
n = 1,185; Scopus via Elsevier, n = 2,837 and Cochrane library, n = 4,052). After de-
duplication 21,063 articles were screened, out of which 390 were shortlisted for full 
review (Figure 1). There was good agreement between reviewers on identifying 
abstracts for full text review. 385 studies were excluded from the systematic review 
and meta-analysis for reasons shown in figure 1. Five fairly recent studies (24, 27-30) 
conducted in developed countries: Israel, Scotland, Sweden and USA  with a total of 
4227 participants met the inclusion criteria of the systematic review. The studies 
investigated national (24), regional (27), Children’s hospital (29), academic medical 
centre (30) and clinic (28) level data.  
 
The Swedish cohort study (24) consisted of 1543 children and adolescents (920 
males) from two nationwide population-based Swedish registries (Swedish Paediatric 
Quality Registry and Swedish National Diabetes Register) and the study period was 
between the years 2000 and 2010. The mean age at diagnosis was 13.9 (Range 5.0 
to 19.0) years and the mean follow-up was for 7.1 ±2.5 (range 1.0 to12.0) years. The 
study investigated whether high mean HbA1c values 3-15 months after diagnosis of 
T1D in childhood was associated with future glycaemic control, albuminuria and 
retinopathy in early adulthood. 
 
The American study (29) prospectively investigated whether age at diagnosis, gender, 
ethnicity, diagnostic era (year of diagnosis) and type of insulin therapy were associated 
with tracking of glycaemic control at five years follow-up post diagnosis of T1D 
between the years 1993 and 2009, in 2218 mainly non-hispanic Caucasian (86.1%) 
children and adolescents (1166 males) with a mean age of 9.0 ±4.1 years at diagnosis 
(range 0 to 20 years), identified from the Children’s Mercy Hospital Type 1 diabetes in 
paediatrics database, USA. Insulin therapy (split regimen dosing, multiple daily 
injections and continuous subcutaneous insulin infusion) and diagnostic methods used 
to analyse HbA1c, varied during the study period. Data on the socio-economic status 
and T1D history in family was not reported. 
 
The other American study (30) was in 138 children (71% males and 91.5% white) at 
an academic medical centre (AMC) of Pediatric Endocrinology/Diabetology at Riley 
Hospital for Children, Indiana, USA and investigated whether the long term HbA1c 
differed as a result of receiving diabetes related education at the AMC as opposed to 
a non–AMC during the years 1998-2002. The mean age at diagnosis was 6.8 ± 3.3 
years (age range: 1.1 – 13.9 years). Details of insulin therapy were not reported. 
 
The Scottish study (27) retrospectively investigated HbA1c tracking among 155 
children (74 males),  aged ≤ 16 years (range 0 to 16 years), from the regional database 
of the National Health Service (NHS) Highland Paediatric diabetic services followed 
for a median of 4.10 (range 0 to 15.0) years from diagnosis between the years 1993 
and 2012. The cohort had limited ethnic diversity, low use of intensive insulin therapy 
and no use of pump therapy.  
 
The Israeli study was a retrospective observational study, investigating HbA1c tracking 
in 173 mainly Jewish (84.4%) preschool aged children (84 males) aged 0.5 – 6.5 years 
at diagnosis between the years 1993 and 2009 at a tertiary level diabetes clinic in 
Israel, with a median T1D duration of 4.3 years (range 1 to 11 years) and followed up 
for seven years from T1D onset (28). All patients were advised on carbohydrate 
counting, required to perform >6 self- blood glucose measurements per day and both 
multiple daily injections and insulin pumps were used.  
 
Further details of the data extracted from the five studies included in the systematic 
review are in Table 1. The quality of the observational studies was intermediate to  
high. Two studies were assessed to be “high” quality with a score of five each (24, 29) 
and the other three were of “intermediate” quality, with scores of four (27, 30) and 
three (28) out of a possible score of six respectively. No studies included in the review 
were of low quality. 
 
Early HbA1c levels and long-term tracking of glycaemic control 
All five studies included in the review assessed the association between early 
glycaemic control and later HbA1c levels. Population mean HbA1c was available at 
various time points (0, 3, 6, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 156 
months after T1D diagnosis) of follow up from these studies. Additionally, data were 
available from four studies (24, 27-29), which also assessed the association between 
early glycaemic control and later HbA1c levels within sub groups of low and high 
HbA1c identified at baseline. 
 
To study the impact of early glycaemic control on later HbA1c levels, data from all five 
studies could be pooled in the review. The number of studies reporting the effect during 
each time point of the study period varied. All studies reported poor estimated mean 
long-term glycaemic control at all of the investigated time points during the 10-year 
follow-up period. The sample size varied from 25 to 1511 and the study period was 
between years 1993 and 2012. After using the population mean HbA1c and SE in the 
FE & RE models, the estimated pooled effect of the mean HbA1c levels (95% CI) was 
suboptimal at 7.61% (CI: 7.47, 7.76%) after 6 months, 7.79% (CI: 7.71, 7.87%) after 
1 year, 7.90%(CI: 7.83, 7.98%) after 2 years, 7.94% (CI: 7.86, 8.03%) after 3 years, 
8.57% (CI: 8.49, 8.65%) after 5 years, 7.99% (CI: 7.85, 8.12%) after 7 years and 
8.59%(CI: 8.24, 8.94%) after 10 years of T1D diagnosis. The pooled results comparing 
the effect size results of the FE and RE models were presented in forest plot (Figure 
2). There was variation in glycaemic control between countries in children and 
adolescents during the 10-year study period. The test for heterogeneity between 
studies was significantly high (I2 >69%) at almost all of the follow-up time points in the 
meta-analysis (χ2 p<0.05).  
 
Further exploratory sub-group analysis indicates that heterogeneity was consistently 
high between studies, countries and populations.   
 
For the assessment of early glycaemic control (low and high HbA1c identified at 
baseline) followed at various time points during the study period, there were four 
studies with data that could be pooled in the review. The HbA1c levels of the low  
HbA1c group showed overall improvement compared to the high HbA1c group during 
the study period but the standardised mean difference between the groups was small 
(Figure 3). The study in pre-school aged children (mean age at diagnosis 3.8 ± 1.6 
years) had better control than the other studies with older children (28). Using the FE 
& RE models, the pooled standardised difference in the decrease in mean HbA1c 
levels from the FE meta-analysis between patients in the exposed group (i.e. low 
HbA1c group) and those in the control group (i.e. the high HbA1c group) with 95% CI 
was significant at -1.25 (-1.53, -0.97) after 6 months, -0.85 (-0.95, -0.75) after 1 year, 
-0.84 (-0.95, -0.74) after 2 years, -0.78 (-0.89, -0.66) after 3 years, -0.44 (-0.54, -0.34) 
after 5 years, -0.75 (-0.94, -0.55) after 7 years and -0.32 (-0.63, -0.02) after 10 years 
of T1D diagnosis. The treatment effect in absolute units was a reduction of HbA1c 
levels by <2.5% after 5 years of T1D diagnosis (Table 2). The heterogeneity levels 
were significantly high (p=0.001) at 1, 2, 3 and 5 years after diagnosis and were lower 
at follow-up time points 0.5, 7 and 10 years after diagnosis (p>0.7) in the meta-
analysis.  
 
The meta-analysis were repeated after excluding the study in pre-school aged children 
(Supplementary figure 1). The pooled standardised mean difference in the decrease 
in HbA1c levels between patients in the exposed group (i.e. low HbA1c group) and 
those in the control group (i.e. the high HbA1c group) with 95% CI was slightly lower 
estimates at -1.10 (-1.56, -0.65) after 6 months, -0.79 (-0.89, -0.69) after 1 year, -0.78 
(-0.89, -0.67) after 2 years, -0.71 (-0.83, -0.59) after 3 years, -0.41 (-0.51, -0.30) after 
5 years, -0.72 (-0.92, -0.53) after 7 years and -0.32 (-0.63, -0.02) after 10 years of T1D 
diagnosis. The test for heterogeneity showed improved results and was significantly 
high only at 5 years after diagnosis (p=0.001) in the meta-analysis (Table 2). 
 
Comparing the long–term HbA1c trajectories between studies revealed that the Israeli 
study in pre-school children yielded better long-term control (supplementary Fig 2). 
Individual study results suggest that early glycaemic control tracks during the follow-
up in the low and high HbA1c groups (Supplementary Fig 3)       
 
Since there were only 5 studies in the review, we could not assess publication bias 
using the funnel plot, the Begg adjusted rank correlation test or the Egger test as there 
was insufficient power to distinguish real asymmetry from random chance.   
 
Association of early HbA1c levels and complications risk 
Only one longitudinal study (24) investigated the association of early glycaemic control 
and future complications and met the inclusion criteria for our systematic review.  The 
study, adjusted for gender, T1D duration, age at diagnosis, physical activity and 
smoking) and reported that Swedish children with higher mean HbA1c levels of ≥ 8.7% 
(≥70 mmol/mol), 3-15 months after diagnosis were significantly more likely to develop 
macroalbuminuria (OR: 14.3, 95% CI: 2.6 to 78.2, p<0.01), microalbuminuria (OR: 1.7, 
95% CI: 0.8 to 3.4, p<0.05) and retinopathy (OR: 2.0, 95% CI: 1.2 to 3.1, p<0.01) in 
early adulthood (mean age: 21± 2.3 years, range: 18 to 29 years). The study also 
highlighted lack of physical activity, smoking and female gender as predictors of poor 
glycaemic control. However, the role of insulin therapies and other social and family 
factors on these observations was not reported. 
 
DISCUSSION 
 
We identified five observational studies investigating the impact of early glycaemic 
control on long-term glycaemic control and risk of developing micro and macro 
vascular complications in children and adolescents (<19 years) followed from 
diagnosis of T1D. In the meta-analysis of all included 5 studies, the overall mean 
HbA1c levels in all studies were sub-optimal at all follow-up time points.  
 
The meta-analysis of the four studies comparing low v/s high HbA1c groups, indicates 
that the low HbA1c group showed overall slightly improved control than the high 
HbA1c group during the study period. Additionally, the meta-analyses suggests that 
the overall glycaemic control was stable in a “track” after 6 months of childhood onset 
T1D diagnosis. The low and high Hba1c levels at baseline also seem to “track” in their 
respective tracks during the 10-year follow-up however, the initial difference between 
groups narrows over time. The number of participants in the low HbA1c group was 
small and this may have influenced the power to detect group differences. 
 
Three of the included studies were of intermediate quality while the remaining two 
were of high quality in reporting potential biases. We adhered to strict systematic 
review procedures for study selection, data extraction and reporting to minimise 
reviewer related biases. The age ranges and sample sizes varied between studies 
which may have influenced the heterogeneity seen in the pooled estimates of long-
term glycaemic control. Heterogeneity was reduced when the study in pre-school 
children was excluded from the meta-analysis. 
 
All studies included in the systematic review were conducted in developed countries, 
which had dissimilar health system models and this may have impacted the long-term 
glycaemic outcomes. The study period was between years 1993 and 2012, which saw 
the evolvement of understanding of the disease and diagnostic methods for HbA1c 
testing. This may have affected the interpretation of the HbA1c measurements. Also, 
several changes were implemented during this period in diabetes care, practise and 
management, through introduction of novel fast acting insulin formulations, intensive 
insulin treatment and educational interventions. These and the improved diagnostic 
and clinic factors may have played a role in improving the overall glycaemic 
trajectories in the participants as reported by other studies (31, 32).  
 
The sub-optimal HbA1c control estimated in the meta-analysis during the follow-up 
period may be due to more participants with higher HbA1c levels, age (33), 
endogenous and exogenous factors or biological variation in the glycation phenotypes 
of children (34-36), psychological factors particularly in older children (37, 38); which 
may have increased the risk of developing or progression of micro & macrovascular 
complications in those children (39). 
 
The DCCT cohort were able to achieve HbA1c levels of 7% (53 mmol/mol) (40) as 
compared with 8.3% (66 mmol/mol) achieved among more than 25,000 patients from 
USA (41) and 8.7% (70.1 mmol/mol) achieved by the paediatric population of England 
and Wales in the UK (42). This highlights the fact that, outside of a clinical trial, 
achieving glycaemic targets remains difficult. Hence robustly identifying factors early 
in the life course of childhood onset T1D that influence future glycaemic control and 
risk of complications remains an important clinical research goal.  
 Only one study provided evidence that albuminuria and retinopathy were associated 
with high mean HbA1c ≥ 8.6% (≥ 70mmol/mol) between 3 and 15 months after 
diagnosis of T1D (24). This is consistent with findings by other studies, which did not 
meet our inclusion criteria (6, 17, 43, 44). It would be highly relevant for determining 
future prognosis, if these outcomes could be confirmed in future studies.  
 
Cardiovascular disease is the major cause of death in T1D patients. Pre-symptomatic 
cardiovascular disease is evident in 100% of young adults with T1D (45) and there is 
evidence of accelerated atherosclerotic processes (46, 47) and increased severity of 
cardiovascular disease (48) at an earlier age compared to the general population. 
Landmark trials show that intensive insulin therapy reduces cardiovascular events (6, 
49). Although differences in HbA1c account for most of this benefit, multivariate 
analyses suggest that part of the reduced risk is mediated by reduction in the incidence 
of diabetic renal disease (50). In children and young people with T1D, atherosclerosis 
is present to a greater extent (51) and the prevalence of cardiovascular risk factors is 
greater (52, 53) than in the general population. Diabetic nephropathy incidence 
accelerates during adolescence (54).  These are all strong indicators of a greatly 
elevated risk for future vascular diseases.  There is currently no evidence base for the 
effectiveness of ACE Inhibition or statin treatments in adolescents with T1D, and the 
important AdDIT Trial may inform practice in the coming years (55).  Therefore 
currently, in order to reduce vascular complications risk, the importance of achieving 
good glycemic control is arguably greater in childhood compared to adult T1D 
populations.  
 
The meta-analysis indicates that the overall glycaemic control stabilizes in a “track” 
after 6 months of childhood onset T1D diagnosis and pre-school aged children had 
better control throughout the follow-up period. Furthermore, the low and high Hba1c 
levels at baseline also seem to have metabolic memory, which shows HbA1c 
“tracking” during the 10-year follow-up despite differences between the high and low 
groups. This suggests there may be benefits of having good control during the initial 
few months of diagnosis. However, as these five studies report temporal associations, 
an experimental study of an intervention soon after diagnosis would be required to 
prove that better early control results in better later control. This review may also 
indicate a short window of opportunity to intervene and improve long-term glycaemic 
outcomes. It may therefore be beneficial to develop clinical and educational strategies 
to identify and deliver targeted interventions during this early phase to those at risk of 
having poor glycaemic control and to ensure that the HbA1c targets are maintained in 
the long-term. There is currently no evidence on effectiveness and timing of focused 
clinical interventions targeted at changing these tracks (18). It would be useful to 
gather this evidence and to explore further the mechanisms of this phenomenon in 
order to deliver best care to newly diagnosed children and adolescents. The findings 
of this review would be useful to policy makers, health professionals and T1D patients 
to focus on designing interventions to prevent sub-optimal glycaemic outcomes and 
decrease the risk of developing micro and macro vascular complications.    
 
Strengths and limitations of the review 
The strengths of this study are many and include, being to our knowledge, the first 
systematic review and meta-analysis to rigorously investigate published and 
unpublished literature on the association of early glycaemic control in childhood onset 
T1D with glycaemic tracking and future risk of complications. Furthermore, this is the 
first review to rigorously and systematically search and review all available evidence 
as per pre-set inclusion/exclusion and quality assessment criteria. We have taken 
utmost care to minimise study selection, reviewer related and publication bias. All of 
the included studies were intermediate to high quality. The overall results were not 
confounded by individual level trajectories. 
 
But, there are limitations to this systematic review which need to be considered. The 
diabetes diagnosis, care and HbA1c outcome measures have evolved over the years 
and were not uniform across studies. There was considerable heterogeneity between 
studies. The comparable follow-up data was not available beyond 10 years. We were 
unable to investigate if other factors may have confounded the findings. The small 
number of studies and the short duration of follow-up in studies may have masked the 
true association with long-term glycaemic control. Although we made every effort to 
search for unpublished and grey literature, we may have missed some that remain 
unreported due to unethical practices in reporting or publication bias. The results of 
our study may not be generalizable as they were mainly conducted in developed 
countries with varied health care system models.  
 
Review updating plans 
The review will be updated if significant new evidence becomes available and results 
of the update review will be disseminated through peer-reviewed publications, 
conference presentations and at meetings.  
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Figure 1: Stages of systematic review of evidence on long-term glycaemic control 
 
 
 
 
  
Total yield of records from electronic database search (after de-duplication): n = 21,063 
Records excluded during title & abstract 
screen stage: n = 20,673 
Full text articles retrieved for detailed review: n = 390 
Studies included in this review: n = 5 (longitudinal observational studies) 
Total articles excluded at this stage: n = 385 
-Inappropriate study design n= 70 
-Inappropriate study population n= 186 
-Inappropriate outcomes/ measures n= 34 
-No association data: n= 89 
-Other (reports, thesis, and letters): n= 6 
Figure 2: Summary of FE & RE models: Pooled estimates of overall glycaemic control at follow-up  
 
FE: fixed effects; RE: random effects; N: number of participants; ES: pooled estimates of HbA1c in absolute units at various time points; I-V: inverse variance; 
D+L: DerSimonian and Laird 
 
 
Fig 3: Summary of FE & RE models: Estimated SMD of change scores with 95% CI between the low 
(exposed to glycaemic control) and high (unexposed to glycaemic control) HbA1c groups during various 
time-points of follow-up 
 
SMD: standardised mean difference; CI: confidence interval; N: number of participants; SD: standard deviation; I-V: inverse variance; D+L: DerSimonian and 
Laird 
 
 
 
 
 
Supplementary Fig 1: Summary of FE & RE models: Estimated SMD of change scores with 95%CI, 
between the low (exposed to glycaemic control) and high (unexposed) HbA1c groups during various 
time-points of follow-up  (Sensitivity analysis - without Shalitin et al 2012) 
 
SMD: standardised mean difference; CI: confidence interval; N: number of participants; SD: standard deviation; I-V: inverse variance; D+L: DerSimonian and 
Laird 
 
 
 
 
 
 
 
 
Supplementary Fig 2: HbA1c trajectories by studies and estimated overall trajectory (using population 
mean and standard error)           
  
 
 
Supplementary Fig 3: HbA1c trajectories by studies (High v/s low)   
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Table 1:  Description of longitudinal studies investigating the impact of early glycaemic control on long-term HbA1c and risk of complications in childhood onset T1D  
 
No Author, 
year,  
country 
and study 
period 
Study design 
and data 
source 
Population Age range 
of study 
population 
Follow-
up 
period 
Treatment Outcome 
and measure 
Definition of  
early HbA1c 
Statistical Analyses Association  Quality 
score (max 
6) and 
comments 
1 Samuelsson 
2014 
 
Sweden 
 
2000 - 2010 
 
Retrospectiv
e/Prospectiv
e pilot study  
 
National 
databases 
(paediatric 
plus adult) 
 
Swedish 
paediatric 
diabetes 
quality 
registry 
(SWEDIABKID
S) and the 
national 
diabetes 
register 
(NDR).  
 
Mean visits 
in SWE: 19.5 
Mean visits 
in NDR: 4 
 
Mean age in 
SWE: 
13.9±2.5 
years 
 
Mean age in 
NDR: 
21.0±2.3 
years 
 
 
 
Generalizability: 
Non rep 
 
Sample size: 1543 
children and 
adolescents. 
 
Males: 920 
 
Ethnicity: NR 
 
SES:NR 
 
Family history of 
T1D:NR 
 
5-9 yr olds: N= 89 
(5.8%) 
10-14 yr olds: N= 
769 (49.8%) 
15-19 yr olds: N= 
685 (44.4%) 
 
 
Mean HbA1c 
adjacent to 
diagnosis: 8.6% 
(≥70mmol/mol ) 
 
Mean HbA1c 
months 3-15 in 
relation to age at 
diagnosis: 
5-9 yr olds: 7.5% ± 
1.1 (58.7 ± 12) 
10-14 yr olds: 7.2% 
± 1.2 (55.3 ± 13) 
5-19 years 
 
Mean age 
at 
diagnosis: 
13.9 ± 2.5 
years. 
 
1-12 
years 
 
Mean:
7.1 
±2.5 
years 
NR Metabolic 
control 
(HbA1c) and 
detection of 
albuminuria, 
retinopathy 
in early 
adulthood 
 
Standardised 
assay for 
HbA1c. 
Urine 
albumin 
excretion.  
Physical 
activity 
levels 
HbA1c values 
between 3 and 15  
15 months after  
diagnosis 
1) MVLR: Mean HbA1c in NDR 
(dependent) and Mean HbA1c 
months 3-15 after diagnosis 
(independent:  
a) Unadjusted: R-square 0.159, Beta 
Coefficient 0.466; 95% CI (0.408 – 
0.525); t=15.6; p=0.001 
  
b) Adjusted (for age at diagnosis, 
gender, duration of diabetes, 
smoking PA): R-square 0.206, Beta 
Coefficient 0.414; 95% CI (0.355 – 
0.473); t=13.2; p=0.001 
 
2) LR unadjusted OR with 95% CI 
a) HbA1c group 6.8 – 8.6%  (51-
69mmol/mol); Ref ≤ 6.7% 
(≤50mmol/mol):  
i) Macroalbuminuria: 1.3 (0.3 - 6.0) 
ii) Microalbuminuria: 0.9 (0.5 -1.4) 
iii) Retinopathy: 1.6 (1.2 – 2.1); 
p<0.01 
 
b) HbA1c group ≥ 8.7% (≥70 
mmol/mol); Ref ≤6.7% 
(≤50mmol/mol):  
i) Macroalbuminuria: 12.3 (3.2 - 
46.8); p<0.01 
ii) Microalbuminuria: 2.0 (1.1 -3.8), 
p<0.05 
iii) Retinopathy: 2.6 (1.7 – 3.8); 
p<0.01 
 
3) LR adjusted (gender, duration of 
T1D, age at diagnosis, PA and 
smoking) OR with 95% CI 
++ Children with poor metabolic 
control adjacent to diagnosis had 
higher HbA1c levels in adulthood. 
 
++ micro and macroalbuminuria and 
retinopathy in early adults seen in 
patients with high mean HbA1c during 
3-15 mo post diagnosis.  
 
++ HbA1c levels higher in young 
children as compared to pubertal 
children (12 y for girls and 14 y for 
boys) 
 
+ girls had higher HbA1c levels 
 
+ PA levels lower in patients with high 
HbA1c levels, micro/macro albuminuria 
and retinopathy 
 
+Smoking observed  in patients with 
high HbA1c levels, micro/macro 
albuminuria and retinopathy 
High (5) 
non-
representati
ve child 
population. 
Children < 5 
years not 
included 
2 
 
 
15-19 yr olds: 7.04% 
± 1.3 (50.5 ± 14) 
 
 
a) HbA1c group 6.8 – 8.6%  (51-
69mmol/mol); Ref ≤6.7% 
(≤50mmol/mol):  
i) Macroalbuminuria: 0.6 (0.1 - 6.9) 
ii) Microalbuminuria: 0.9 (0.6 -1.7) 
iii) Retinopathy: 1.4 (1.1 – 1.9); 
p<0.05 
 
b) HbA1c group ≥ 8.7% (≥70 
mmol/mol); Ref ≤ 6.7%  
≤50mmol/mol):  
i) Macroalbuminuria: 14.3 (2.6 - 
78.2); p<0.01 
ii) Microalbuminuria: 1.7 (0.8 -3.4) 
iii) Retinopathy: 2.0 (1.2 – 3.1); 
p<0.01 
2 Clements 
2014 
 
USA 
 
1993 - 2009 
Prospective 
cohort 
 
The 
Children’s 
Mercy 
Hospital Type 
1 diabetes in 
paediatrics 
database, 
USA. 
Generalizability: 
Rep 
 
Sample size: 2218 
children and 
adolescents. 
 
Males: 1166 
 
Ethnicity: 86.1% 
non-Hispanic 
Caucasian, 8.9% 
non-Hispanic 
African-American, 
5% other or 
Hispanic), 
 
SES:NR 
 
Family history of 
T1D:NR 
 
 
 
 
0-20 years 
 
Mean age 
at 
diagnosis: 
9.0 ±4.1 
years 
 
5 years Stratified 
by 
diagnostic 
era which 
included 
the 
following 
regimen as 
first line 
therapy 
 
Pre 2000: 
Split 
regimen 
dosing 
 
2000-
2003: 
multiple 
daily 
injections 
 
2004-
2009:  
Continuou
s 
subcutane
ous insulin 
infusion 
1)Associatio
n with 
HbA1c levels 
at diagnosis, 
1.5  and 5 
year f/u by 
diagnostic 
age, 
ethnicity, 
and 
diagnostic 
era 
 
Various 
methods 
used to 
measure 
HbA1c 
during the 
study period 
i.e. HPLC, 
Boronate 
affinity. 
 
2) Effect of 
insulin 
therapy on 
HbA1c 
tertiles i.e. 
 HbA1c during 
first 3 months 
of diagnosis 
and/or 4 – 12 
months after 
diagnosis 
 
Three groups 
of patients 
based on 
baseline 
HbA1c: a) <7, 
b) 7 to 9, c) 
>9.   
Mean (SD) 1st HbA1c after 3months 
of diagnosis 7.7 ± 1.9 (60.7 ±20.8 
mmol/mol) 
 V/S  
mean HbA1c in the 5th year after 
diagnosis 9.2 ± 1.8 (106.6 ±28.0 
mmol/mol) 
  
Comparison of mean 1st HbA1c 
after 3months of diagnosis V/S 
mean HbA1c in the 5th year after 
diagnosis by HbA1c tertiles < 7, 7-9 
and > 9 % (< 53, 53 -75 and >75 
mmol/mol) 
 
(1) HbA1c in children with < 7: mean 
6.2 ± 0.5 (n = 871) v/s 9.1 ± 1.8 (n = 
609 missing) 
(2) HbA1c 7 – 9: mean 7.9 ± 0.6 (n = 
940) v/s 9.1 ± 1.5 (n=483 missing) 
(3) HbA1c > 9: mean 10.7 ± 1.8 (n = 
407) v/s 9.8 ± 2.0 (n=201 missing) 
 
Regression, stratified analyses 
 
Effect of insulin therapy: 
Children with <7% (53mmol/mol) at 
diagnosis had higher HbA1c levels 
++ Significant increase in HbA1c levels 
by increasing age of diagnosis with ≥10 
year olds experiencing poorer 
glycaemic control. Younger patients 
had better control across all HbA1c sub 
categories p<0.001 
 
The group with HbA1c <7 has steeper 
increase for the first 1.5 years. 
However, it seems all three groups 
ended at about the same level at 5 
years except for the patients who were 
diagnosed at >10 years old of the 
HbA1c >9 group.   
 
++ 0-4 year old did not show much 
change in HbA1c trajectory over 5 
years, but progressive increase in 
HbA1c levels in all age groups, highest 
in >10 year olds (p<0.001). 
Highest HbA1c inflection point is at 
around 1.5 years post diagnosis 
 
++ Small but statistically significant 
differences within gender subgroups 
across diagnostic age groups 
(p<0.0001).  
 
High (5) 
 
5 different 
methods 
used to 
analyse 
HbA1c 
during the 
study period 
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Children 
with <7% 
(<53mmol/m
ol), 7-9% 
(53-
75mmol/mol
) and >9% 
(>75%)  
 
 
during 1.5 years after diagnosis 
across all age groups. 
 
Overall HbA1c levels rose yearly by 
1.83% (1.72 to 1.94) (20.0 
mmol/mol (18.8 to 20.2). 
 
HbA1c rise was less steep but 
significant in children with baseline 
HbA1c between 7% (53mmol/mol) 
and 9% (75mmol/mol) (0.81% (0.69 
to 0.92) (8.9 mmol/mol (7.5 to 
10.1))).  
 
Patients with baseline HbA1c >9% 
(75mmol/mol) had stable or 
improved control at 1.5 years post 
diagnosis with an overall  yearly 
decline of -0.68% (-0.87 to -0.49) per 
year (-7.4 mmol/mol (-9.5 to -5.3) 
 
Non- Hispanic black v/s non- 
Hispanic white mean (SD): 10.2% 
(±2.5) (88.0 ±27.3 mmol/mol) and 
8.4% (±1.4) (68.0 ±15.3 mmol/mol) 
 
Pre 2000 era mean (SD): 8.9% (±1.5) 
(73.8 ±16.4 mmol/mol)  
2000-2003 mean (SD): 8.7% (±1.6) 
(71.6 ±17.5 mmol/mol) 
2004-2009 mean (SD): 8.1% (±1.7) 
(65.0 ±18.6 mmol/mol) 
++ HbA1c levels were higher in non-
Hispanic black patients (p value for 
race/ethnicity x age interaction <0.001 
Also rate of HbA1c levels rise during 
1.5 years post diagnosis was greater in 
non- Hispanic black patients in each 
age sub group. 
 
++ high levels in pre 2004-2009 group 
at diagnosis, 1.5 and 5 years p<0.001. 
3 Lawes 2014 
 
 
North of 
Scotland, 
UK 
 
Jan 1993 – 
Aug 2012 
 
 
Retrospectiv
e cohort 
 
Regional 
database 
(paediatric) 
from NHS 
Highland 
Paediatric 
diabetic 
services, 
North of 
Scotland, 
Generalizability: 
Non rep 
 
Sample size: 155 
children ≤ 16 years. 
 
Males: n= 74. 
 
Ethnicity: limited 
ethnic diversity 
 
SES and family 
history of T1D: 
0-16 years 
 
Median 
baseline 
age: 7.9 
(range 4.5 
to 10.9 
years). 
 
Up to 
15 
years 
 
 
Media
n f/u: 4 
years 
10 
month
s 
Lower use 
of 
intensive 
insulin 
(basal 
bolus) 
regimens. 
 
No 
patients 
on pump 
therapy. 
HbA1c 
trends and 
association 
with 6 
month 
HbA1c  
 
Bayer DCA 
2000 near-
patient 
analyser 
 
Baseline 
HbA1c  
defined as 
HbA1c at or 
nearest to 6 
months from 
diagnosis 
LMR: 0.9% (10mmol/mol) increase 
at 6 month HbA1c was associated 
with 0.5% (0.4-0.6%) or 
5.3mmol/mol (4.5-6.2) increase at 
all subsequent time points (95% CI: 
p<0.001) 
 
A 2.4% (1.1 to 3.6%) or 26 
mmol/mol (12 to 39) increase in 
HbA1c was seen at 10 year f/u in 
patients from highest 6 months 
HbA1c quintile (8.6 vs 6.2% or 94 vs 
68mmol/mol) p<0.001 
++ Significant mean HbA1c levels and 
shape of trajectories after adjusting for 
patient and observation level 
predictors. 
 
++A higher 6 month HbA1c was 
associated with slow but sustained 
HbA1c deterioration with T1D duration 
as compared to lower 6 month HbA1c  
 
Time independent variables 
significantly associated with poorer 
glycaemic control were age at 
Intermediate 
(4)  
Retrospectiv
e study 
design. Non-
rep - 
excluded 
patients with 
< 1 year f/u 
from 
diagnosis. 
Included 
only patients 
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study reports as 
nationally 
comparable 
 
40% patients lived 
in remote/rural 
areas.  
 
 
 
3121 HbA1c 
measuremen
ts 
 
 
 
Cross-correlation coefficients for 6-
months HbA1c on linear and 
quadratic growth identified 
sustained effects on trajectories of 
glycaemic control (p<0.001) 
 
 
diagnosis, living with <2 biological 
parents, proximity to urban clinic, 
neighbourhood deprivation, child with 
welfare concerns and with thyroid 
disease. 
 
Time dependent covariates: mental 
health problems, major adverse life 
events, clinic non- attendance, lower 
BMI SDS (particularly in girls), were 
associated with higher HbA1c levels.   
from North 
Scotland. 
 
Attrition rate 
was high 
(approx. 
80%) at 10 
year f/u 
4 Shalitin 
2012 
 
Israel 
 
Jan 1999 – 
May 2009 
Retrospectiv
e cohort 
 
Diabetes 
clinic 
database 
within a 
tertiary 
hospital - the 
National 
Center for 
Childhood 
Diabetes, 
Schneider 
Children’s 
Medical 
Center of 
Israel.  
 
Generalizability: 
Non rep 
Sample size: 173 
pre-school aged 
children 0.5 to 6.5 
years  
 
Males = 84  
 
Ethnicity: 
Jews=84.4%, 
Arabs=12.1% and 
Ethiopian 
Jews=3.5% 
 
 
SES: only parental 
marital status 
reported 
 
Family history of 
T1D: NR 
 
Mean duration of 
diabetes: 4.9 ±2.8 
years or median 4.3 
(range 1 – 11 years)  
0.5 – 17 
years 
 
Mean age 
at 
diagnosis: 
3.8 ± 1.6 
years 
0 – 7 
years 
 
 
All 
patients 
were 
advised on 
carbohydr
ate 
counting, 
required 
to perform 
self- blood 
glucose 
measurem
ents at 
least 6 
times/day 
and 
several 
different 
types of 
insulin 
regimen 
(multiple 
daily 
injections 
or 
continuou
s 
subcutane
ous insulin 
infusion) 
were used. 
HbA1c 
trends (in 
patients with 
<7.5% (n=53) 
and ≥7.5% 
(n=120) 
HbA1c) and 
association 
with HbA1c 
at onset 
 
Capillary 
HbA1c 
measured 
every 3 
months by 
automated 
immunoche
mical 
technique 
using Bayer 
DCA 2000; 
reference 
range 4.3 – 
5.8%. 
 
During f/u: 
HbA1c <7.5% 
: n=53  
(30.6% 
patients) 
HbA1c ≥7.5% 
: n=120  
HbA1c at T1D 
onset 
MLRA: OR=0.44; 95% CI0.26-0.72; 
p=0.002 and OR=0.09; 95% CI 0.04-
0.24; P<0.001 for every 1% increase 
in HbA1c at 0.5 and 1 year after T1D 
onset.    
 
HbA1c in patients with  <7.5% :  
At onset: 9.5 ±2.1 (n=53) 
At 0.5 years after onset: 6.8 ±0.9 
(n=53) 
At 1 years after onset: 7.0 ±0.6 
(n=53) 
At 2 years after onset: 7.1 ±0.5 
(n=42) 
At 3 years after onset: 7.1 ±0.5 
(n=37) 
At 4 years after onset: 7.2 ±0.6 
(n=26) 
At 5 years after onset: 6.8 ±0.5 
(n=14) 
At 6 years after onset: 6.8 ±0.3 
(n=11) 
At 7 years after onset: 6.9 ±0.3 (n=4) 
HbA1c at last visit: 7.3±0.7 
 
HbA1c in patients with  >7.5% :  
At onset: 10.2 ±1.8 (n=120) 
At 0.5 years after onset: 8.3 ±1.2 
(n=120) 
At 1 years after onset: 8.4 ±0.9 
(n=120) 
At 2 years after onset: 8.3 ±0.8 
(n=98) 
++ Lower HbA1c values at 0.5 and 1 
year after T1D onset, predicted 
achievement of HbA1c target of <7.5%.  
 
 
++ comparison of HbA1c between 
below target and above <7.5% target in 
patients was significant 
 
++ Patients with celiac disease (n=21) 
had lower mean HbA1c compared to 
those without (n=152). 7.5 ±0.8% vs 8.0 
±0.8%, p=0.01 
 
+ children from single parent family 
and those with more DKA events had 
higher HbA1c levels, but this was not 
statistically significant 
 
There were no statistically significant 
differences between groups in Gender, 
ethnicity, age at diagnosis, presence of 
diabetes antibodies, and presence of 
DKA at onset, mean number of SBGM 
and insulin regimen type (MDI or 
CSSII). 
Intermediat
e (3) 
retrospectiv
e study 
design; non-
representati
ve child 
population. 
Children < 
0.5 years 
and >6.5 
years at 
baseline not 
included, 
analyses.  
 
Attrition rate 
was 62, 66 
and 73% at 
5, 6 and 7 
year f/u 
respectively. 
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(69.4% 
patients) 
 
Attrition rate 
was 62, 66 
and 73% at 
5, 6 and 7 
year f/u 
respectively. 
At 3 years after onset: 8.4 ±0.8 
(n=79) 
At 4 years after onset: 8.4 ±0.8 
(n=68) 
At 5 years after onset: 8.4 ±0.9 
(n=57) 
At 6 years after onset: 8.4 ±0.9 
(n=47) 
At 7 years after onset: 8.3 ±1.0 
(n=42) 
HbA1c at last visit:8.4±1.0 
5 Cabrera 
2013 
 
USA 
 
1998 –2002 
Retrospectiv
e cohort 
 
Electronic 
clinical 
database of 
the Section 
of Pediatric 
Endocrinolog
y/Diabetolog
y at Riley 
Hospital for 
Children, 
Indiana, USA 
Generalizability: 
Rep 
Sample size: 138 
children 1.1 – 13.9 
year  old 
 
Males = 71  
 
Ethnicity: 
white=91.5%, 
other=8.5%  
 
SES: parental 
marital status and 
insurance type 
reported 
 
Family history of 
T1D: NR 
 
Mean duration of 
diabetes: 5 years 
1.1 – 13.9 
years 
 
Mean age 
at 
diagnosis: 
6.8 ± 3.3 
years 
0 – 5 
years 
 
 
Patients 
with initial 
T1D 
education 
from 
academic 
medical 
center 
(AMC) V/S 
non-AMC 
patients 
 
Insulin 
therapy: 
NR 
HbA1c levels 
at 0, 2, 3 and 
5 years after 
diagnosis in 
AMC v/s non 
AMC 
referred 
patients. 
 
  
Initial A1C by 
either by 
Bayer 
DCA2000 or 
by HPLC at 
the central 
lab. All 
patients 
subsequentl
y had their 
A1C 
determined 
by the Bayer 
DCA2000 at 
follow-up 
clinic visits. 
A1C levels 
were 
obtained 
from the 
records of 
subsequent 
clinic visits, 
and mean 
HbA1c at T1D 
onset 
Mean (SE): At diagnosis: 9.53(0.24) 
 
GEE Mean(SE): at 2 years: 8.81(0.09) 
at 3 years:8.94(0.12) 
at 5 years: 8.84(0.12) 
   
Correlations of A1C values over 
time for all individual patients 
(p<0.001) 
Change from 2 to 3 years (n=130): 
0.648 
Change from 2 to 5 years (n=130): 
0.524 
Change from 3 to 5 years (n=138): 
0.520 
 
The A1C was also highly consistent in 
each patient over time. 
/ Long-term glycaemic control was 
independent of whether initial 
education was delivered at an AMC or 
non-AMC.  
/ Formal education and location at 
time of diagnosis do not appear to play 
a significant role in long-term 
glycaemic control. 
Intermediate 
(4) 
retrospectiv
e study 
design; 
analyses.  
 
Attrition rate 
appears to 
be 8 at 2 and 
3 years  
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A1C was 
calculated 
for years 2, 
3, and 5 
from date of 
diagnosis. 
 
T1D: Type 1 diabetes; NON REP: Non representative of general population; SD: standard deviation; BMI SDS: Body mass index standard deviation score; PA: physical activity; MVLR: Multivariate linear regression; LMR: linear 
multilevel regression; MLRA: Multiple logistic regression Analysis; GEE: Generalised estimating equation; CI: confidence intervals; LR: logistic regression; OR: Odds ratio; ++: statistically significant positive association; + or - : 
statistically non- significant positive or negative association 
 
 
 
Table 2: Summary of change scores in Meta-analysis comparing pooled standardised mean differences between low and high HbA1c groups  
 MA with all 4 studies Sensitivity MA (after excluding study in pre-school children) 
T1D duration SMD (95% CI) HbA1c % (95% CI) Heterogeneity (I2) SMD (95% CI) HbA1c % (95% CI) Heterogeneity (I2) 
after 6 months of T1D diagnosis -1.25 (-1.53, -0.97) -2.28% (-2.79%, -1.77%) 0.0%, p=0.41 -1.10 (-1.56, -0.65) -2.37% (-3.35%, -1.40%) 0.0%, p=0.01 
after 1 year of T1D diagnosis -0.85 (-0.95, -0.75) -2.02% (-3.06%, -0.97%) 91.0%, p=0.001 -0.79 (-0.89, -0.69) -1.74% (-1.96%, -1.52%) 0.0%, p=0.61 
after 2 years of T1D diagnosis -0.84 (-0.95, -0.74) -1.76% (-2.63%, -0.90%) 87.8%, p=0.001 -0.78 (-0.89, -0.67) -1.48% (-1.69%, -1.27%) 0.0%, p=0.73 
after 3 years of T1D diagnosis -0.78 (-0.89, -0.66) -1.75% (-2.80%, -0.70%) 90.5%, p=0.001 -0.71 (-0.83, -0.59) -1.48% (-1.73%, -1.23%) 0.0%, p=0.93 
after 5 years of T1D diagnosis -0.44 (-0.54, -0.34) -1.25% (-2.03%, -0.48%) 90.9%, p=0.001 -0.41 (-0.73, -0.09) -0.90% (-1.60%, -0.20%) 85.7%, p=0.001 
after 7 years of T1D diagnosis -0.75 (-0.94, -0.55) -1.19% (-1.62%, -0.74%) 16.6%, p=0.30 -0.72 (-0.92, -0.53) -1.48% (-1.89%, -1.09%) 0.0%, p=0.40 
after 10 years of T1D diagnosis -0.32 (-0.63, -0.02) -0.95% (-1.87%, -0.06%) 0.0%, p=0.67 -0.32 (-0.63, -0.02) -0.95% (-1.87%, -0.06%) 0.0%, p=0.67 
MA: Meta-analysis; SMD: standardised mean difference, T1D: Type 1 diabetes; HbA1c: Glycated Haemoglobin  
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Additional File 1: Search Strategy for research questions: Impact of early glycaemic control on long-term HbA1c and risk of complications.  
Population Exposure Outcome 
Childhood or paediatric onset diabetes or 
juvenile diabetes diagnosis or newly 
diagnosed children or young persons or 
young people or children or young or 
adolescent or teen or youth or adult T1D 
patient or type 1 diabetes or T1D or type 1 
diabetes mellitus or T1DM or DM1 or type 
1 or IDDM or insulin dependent or non-
insulin dependent or childhood onset 
diabetes or childhood onset T1D or auto-
immune or autoimmune or sudden onset 
or uncontrolled or labile or brittle 
Early diabetes control or HbA1c 
trajectories or HbA1c trends or glycaemic 
trajectories or glycosylated or HbA1c or 
A1c or Hemoglobin A or HbA(1c) level or 
glycaemic control or glucose control or 
diabetes control or early intensive 
intervention or intensive or conventional 
or standard or regular or optimised or 
tight control or strict control or usual or 
routine or therapy or treatment or 
intervention or management or insulin 
use or injection or dose insulin injections 
or intensive therapy or insulin pump 
Diabetic or diabetes complications or complications or side effects or adverse 
events or acute complications or chronic complications or 
glycaemia or hyper glycaemia or hypo glycaemia or ketosis or diabetic 
ketoacidosis or DKA or nonketotic hyperosmolar coma or insulin resistance or 
autoimmune disease or urine albumin or urine albumin creatinine ratio or 
urine albumin excretion or microalbuminuria or macroalbuminuria or renal 
disease or diabetic nephropathy or nephropathy or dialysis or foot ulcer or 
amputation or retinopathy or blindness or vascular disease or vascular 
complications or microvascular disease or microvascular complications or 
macrovascular  disease or macrovascular complications or cardiovascular 
disease or MI or myocardial infarction or stroke or coronary artery disease or 
cerebrovascular disease or peripheral vascular disease or blood pressure or BP 
or statin or death or mortality or Pathology or metabolism or metabolic 
memory 
 
Additional File 2: Electronic database search strategy 
I.  Scopus (via Elsevier) (Original: 17/12/2014; Updated: 17/02/2017) 
1. ( TITLE-ABS-KEY ( ( {early intensive}  OR  tight  OR  glycemic  OR  glycaemic  OR  glucose  OR  diabetes  OR  strict )  W/2  control )  OR  TITLE-ABS-KEY ( insulin  W/2  ( 
use*  OR  injection*  OR  dose*  OR  pump* ) )  OR  TITLE-ABS-KEY ( glycosylat*  OR  {HbA1c}  OR  a1c  OR  hemoglobin  a  OR  haemoglobin  OR  {HbA(1c)} )  OR  
TITLE-ABS-KEY ( ( intensive  OR  conventional  OR  standard  OR  regular  OR  optimised  OR  usual  OR  routine )  W/2  ( care  OR  treatment  OR  therapy  OR  
intervention  OR  management ) )  OR  TITLE-ABS-KEY ( hyperglycaemia  OR  hypoglycaemia ) )  AND  ( TITLE-ABS-KEY  OR ( {Diabetes complication*}  OR  {side 
effects}  OR  {adverse events}  OR  glycemia  OR  glycaemia  OR  {hyper glycemia}  OR  {hyper glycaemia}  OR  hyperglycemia  OR  hyperglycaemia  OR  {hypo 
glycemia}  OR  {hypo glycaemia}  OR  hypoglycemia  OR  hypoglycaemia )  OR  TITLE-ABS-KEY ( ketosis  OR  {diabetic ketoacidosis}  OR  dka  OR  {nonketotic 
hyperosmolar coma}  OR  {insulin resistance}  OR  {autoimmune disease*}  OR  {auto immune disease} )  OR  TITLE-ABS-KEY ( {urine albumin}  OR  microalbuminaria  
OR  macroalbuminuria  OR  {renal disease*}  OR  {kidney disease*}  OR  {diabetic nephropathy}  OR  nephropathy  OR  dialysis )  OR  TITLE-ABS-KEY ( {foot ulcer}  OR  
amputation )  OR  TITLE-ABS-KEY ( retinopathy  OR  blindness  OR  {cardiovascular disease*}  OR  mi  OR  {myocardial infarction*}  OR  stroke*  OR  {coronary artery 
disease*} )  OR  TITLE-ABS-KEY ( {cerebrovascular disease*}  OR  {peripheral vascular disease*}  OR  {blood pressure}  OR  bp  OR  statin*  OR  death  OR  mortality ) )  
AND  ( TITLE-ABS-KEY ( pediatric  OR  paediatric  OR  child*  OR  {young people}  OR  youth  OR  {young adult*}  OR  juvenile  OR  {insulin dependent}  OR  labile  OR  
brittle  OR  {sudden onset}  OR  autoimmune  OR  {auto immune}  OR  {non insulin dependent}  OR  uncontrolled  OR  {newly diagnosed}  OR  {new diagnosis}  OR  
{inception diabetes} ) )  AND  ( TITLE-ABS-KEY ( dm1  OR  {diabetes mellitus 1}  OR  {diabetes mellitus}  W/2  {type 1} )  OR  t1d  OR  t1dm  OR  iddmor  {type 1} )  AND  
TITLE-ABS-KEY ( metabolism  OR  {metabolic memory} )   
2 TITLE-ABS-KEY ( metabolism  OR  {metabolic memory} )  
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3 (TITLE-ABS-KEY or ({Diabetes complication*} or {side effects} or {adverse events} or glycemia or glycaemia or {hyper glycemia} or {hyper glycaemia} or hyperglycemia 
or hyperglycaemia or {hypo glycemia} or {hypo glycaemia} or hypoglycemia or hypoglycaemia) or TITLE-ABS-KEY (ketosis or {diabetic ketoacidosis} or DKA or 
{nonketotic hyperosmolar coma} or {insulin resistance} or {autoimmune disease*} or {auto immune disease}) or TITLE-ABS-KEY ({urine albumin} or microalbuminaria 
or macroalbuminuria or {renal disease*} or {kidney disease*} or {diabetic nephropathy} or nephropathy or dialysis) or TITLE-ABS-KEY ({foot ulcer} or amputation) or 
TITLE-ABS-KEY (retinopathy or blindness or {cardiovascular disease*} or MI or {myocardial infarction*} or stroke* or {coronary artery disease*}) or TITLE-ABS-KEY 
({cerebrovascular disease*} or {peripheral vascular disease*} or {blood pressure} or BP or statin* or death or mortality)) 
4 (TITLE-ABS-KEY (({early intensive} or tight or glycemic or glycaemic or glucose or diabetes or strict) W/2 control) OR TITLE-ABS-KEY (insulin W/2 (use* or injection* or 
dose* or pump*)) OR TITLE-ABS-KEY (glycosylat* or {HbA1c} or A1c or Hemoglobin A or haemoglobin or {HbA(1c)}) OR TITLE-ABS-KEY((intensive or conventional or 
standard or regular or optimised or usual or routine) W/2 (care or treatment or therapy or intervention or management)) OR TITLE-ABS-KEY (hyperglycaemia or 
hypoglycaemia)) 
5 ( TITLE-ABS-KEY ( pediatric  OR  paediatric  OR  child*  OR  {young people}  OR  youth  OR  {young adult*}  OR  juvenile  OR  {insulin dependent}  OR  labile  OR  brittle  
OR  {sudden onset}  OR  autoimmune  OR  {auto immune}  OR  {non insulin dependent}  OR  uncontrolled  OR  {newly diagnosed}  OR  {new diagnosis}  OR  {inception 
diabetes} ) )  
6 ( TITLE-ABS-KEY ( dm1  OR  {diabetes mellitus 1}  OR  {diabetes mellitus}  W/2  {type 1} )  OR  t1d  OR  t1dm  OR  iddmor  {type 1} )   
 
 
II.  Cochrane Library (Original: 17/12/2014; Updated: 17/02/2017) 
#1
  
MeSH descriptor: [Diabetes Mellitus, Type 1] explode all trees 
#2
  
DM1 or diabetes mellitus 1 or diabetes mellitus type 1 or T1D or T1DM or IDDM 
#3 type 1 or paediatric or child or young people or youth or young adults or juvenile or insulin dependent or labile or brittle or sudden onset or autoimmune or auto 
immune or non insulin dependent or uncontrolled or newly diagnosed or new diagnosis or inception diabetes 
#4
  
#1 or #2 or #3 
#5
  
MeSH descriptor: [Blood Glucose] explode all trees  
#6 MeSH descriptor: [Hemoglobin A, Glycosylated] explode all trees  
#7
  
MeSH descriptor: [Hypoglycemia] explode all trees  
#8
  
MeSH descriptor: [Hyperglycemia] explode all trees 
#9 #5 or #6 or #7 or #8   
#10
  
early intensive or tight or glycemic or glucose or diabetes or strict control   
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#11
  
insulin use or injection or dose or pump  
#12 glycosylate or HbA1c or A1c or Hemoglobin A or HbA1c  
#13 intensive or conventional or standard or regular or optimised or usual or routine care or treatment or therapy or intervention or management   
#14
  
#9 or #10 or #11 or #12 or #13  
#15
  
MeSH descriptor: [Diabetes Complications] explode all trees 
#16
  
adverse effects or complications   
#17
  
MeSH descriptor: [Ketosis] explode all trees  
#18
  
MeSH descriptor: [Insulin Resistance] explode all trees 
#19 MeSH descriptor: [Autoimmune Diseases] explode all trees 
#20
  
MeSH descriptor: [Albuminuria] explode all trees  
#21
  
MeSH descriptor: [Kidney Diseases] explode all trees 
#22
  
MeSH descriptor: [Dialysis] explode all trees  
#23
  
MeSH descriptor: [Blindness] explode all trees 
#24
  
MeSH descriptor: [Cardiovascular Diseases] explode all trees 
#25
  
MeSH descriptor: [Cerebrovascular Disorders] explode all trees 
#26 MeSH descriptor: [Blood Pressure] explode all trees 
#27
  
MeSH descriptor: [Hydroxymethylglutaryl-CoA Reductase Inhibitors] explode all trees 
#28
  
MeSH descriptor: [Mortality] explode all trees 
#29
  
Diabetes complications or side effects or adverse events or glycaemia or hyper glycaemia or hypo glycaemia or ketosis or diabetic ketoacidosis or DKA or nonketotic 
hyperosmolar coma or insulin resistance or autoimmune disease or urine albumin or urine albumin creatinine ratio or urine albumin excretion or microalbuminuria 
or macroalbuminuria or renal disease or diabetic nephropathy or nephropathy or dialysis or foot ulcer or amputation or retinopathy or blindness or cardiovascular 
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disease or MI or myocardial infarction or stroke or coronary artery disease or cerebrovascular disease or peripheral vascular disease or blood pressure or BP or 
statin or death or mortality  
  
#30
  
#15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29  
#31
  
metabolism   
#32
  
metabolic memory  
#33
  
#31 or #32   
#34
  
#4 and #9 and #14 and #30 and #33  
 
 
III.  CINAHL Plus (via EBSCO) (Original: 16/12/2014; Updated: 17/02/2017) 
S34  S4 AND S14 AND S30 AND S33   
S33  S31 OR S32   
S32  "metabolic memory"   
S31  MJ metabolism   
S30  S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29   
S29  
diabetes complication or diabetes complication* or side effects or adverse events or glyc#emia or hyper glyc#emia or hyperglyc#emia or hypo glyc#emia or 
hypoglyc#emia or ketosis or diabetic ketoacidosis or DKA or nonketotic hyperosmolar coma or insulin resistance or autoimmune disease* or urine albumin or 
microalbuminaria or macroalbuminuria or renal disease* or kidney disease* or diabetic nephropathy or nephropathy or dialysis or foot ulcer or amputation or 
retinopathy or blindness or cardiovascular disease* or MI or myocardial infarction* or stroke* or coronary artery disease* or cerebrovascular disease* or peripheral 
vascular disease* or blood pressure or BP or statin* or death or mortality 
S28  (MH "mortality+")   
S27  (MH "statins+")   
S26  (MH "blood pressure+")   
S25  (MH "cerebrovascular disorders+")   
S24  (MH "stroke+")   
11 
 
 
S23  (MH "cardiovascular diseases+")   
S22  (MH "blindness+")   
S21  (MH "dialysis+")   
S20  (MH "kidney diseases+")   
S19  (MH "Albuminuria")   
S18  (MH autoimmune diseases+)   
S17  (MH insulin resistance+)   
S16  (MH "diabetic angiopathies+") OR (MH "diabetic cardiomyopathies") OR (MH "diabetic coma+") OR (MH "diabetic ketoacidosis") OR (MH "diabetic neuropathies+")   
S15  (MH "diabetes mellitus/co")   
S14  S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13   
S13  (intensive OR conventional OR standard OR regular OR optimi#ed OR usual OR routine) N2 (care OR treatment OR therapy OR intervention OR management)   
S12  glycosylat* OR HbA1c OR A1c OR H#emoglobin A OR HbA#1c   
S11  insulin N2 (use* OR injection* OR dose* OR pump*)   
S10  (“early intensive” OR tight OR glyc#emic OR glucose OR diabetes or strict) N2 control)   
S9  (MH "Hyperglycemia+")   
S8  (MH "Hypoglycemia+")   
S7  MH blood glucose   
S6  MH hemoglobin A, glycosylated   
S5  (MH "Glycemic Control")   
S4  S1 OR S2 OR S3   
S3  ("type 1" OR p#ediatric OR child* OR "young people" OR youth OR "young adult" OR juvenile OR "insulin dependent" OR labile OR brittle OR "sudden onset" OR autoimmune OR "auto immune" OR "non insulin dependent" OR uncontrolled OR "newly diagnosed" OR "new diagnosis" OR inception) N5 diabetes   
S2  DM1 OR "diabetes mellitus 1" OR ("diabetes mellitus" N2 type 1) OR T1D or T1DM or IDDM   
S1  (MH "Diabetes Mellitus, Type 1+")   
 
 
IV.  Web of Science (via Thomson Reuters) (Original: 16/12/2014; Updated: 17/02/2017) 
1 
TOPIC: ((DM1 OR "diabetes mellitus 1" OR ("diabetes mellitus" NEAR/2 "type 1") OR T1D or T1DM or IDDM) OR TOPIC: (("type 1" OR p$ediatric OR child* OR "young 
people" OR youth OR "young adult" OR juvenile OR "insulin dependent" OR labile OR brittle OR "sudden onset" OR autoimmune OR "auto immune" OR "non insulin 
dependent" OR uncontrolled OR "newly diagnosed" OR "new diagnosis" OR inception) NEAR/5 diabetes)) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, CCR-EXPANDED, IC Timespan=All years 
2 
TOPIC: (TOPIC: ((“early intensive” OR tight OR glyc$emic OR glucose OR diabetes or strict) NEAR/2 control) OR TOPIC: (insulin NEAR/2 (use* OR injection* OR dose* 
OR pump*)) OR TOPIC: (glycosylat* OR HbA1c OR A1c OR H$emoglobin A OR HbA$1c) OR TOPIC: ((intensive OR conventional OR standard OR regular OR optimi$ed 
OR usual OR routine) NEAR/2 (care OR treatment OR therapy OR intervention OR management)) OR TOPIC: (hyperglyc$emia OR hypoglyc$emia)) 
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Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, CCR-EXPANDED, IC Timespan=All years 
3 
TOPIC: (TOPIC: (“Diabetes complication*” OR “side effects” OR “adverse events” OR glyc$emia OR “hyper glyc$emia” OR hyperglyc$emia OR “hypo glyc$emia” OR 
hypoglyc$emia OR ketosis OR “diabetic ketoacidosis” OR DKA OR “nonketotic hyperosmolar coma” OR “insulin resistance” OR “autoimmune disease*” OR “auto 
immune disease” OR “urine albumin” OR microalbuminaria OR macroalbuminuria OR “renal disease*” OR “kidney disease*” OR nephropathy OR dialysis OR “foot 
ulcer” OR amputation OR retinopathy OR blindness OR “cardiovascular disease*” OR MI OR “myocardial infarction*” OR stroke* OR “coronary artery disease*” OR 
“cerebrovascular disease*” OR “peripheral vascular disease*” OR “blood pressure” OR BP OR statin* OR death OR mortality)) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, CCR-EXPANDED, IC Timespan=All years 
4 TOPIC: (TOPIC: (metabolism OR "metabolic memory" OR metabolic)) Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, CCR-EXPANDED, IC Timespan=All years 
5 #4 AND #3 AND #2 AND #1  DocType=All document types; Language=All languages; 
 
 
 
V.  EMBASE (via OVID) (Original: 16/12/2014; Updated: 17/02/2017) 
1 exp insulin dependent diabetes mellitus/ 
2 (DM1 or diabetes mellitus 1 or (diabetes mellitus adj2 type 1) or T1D or T1DM or IDDM).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading] 
3 
((type 1 or p?ediatric or child* or young people or youth or young adults or juvenile or insulin dependent or labile or brittle or sudden onset or autoimmune or auto 
immune or non insulin dependent or uncontrolled or newly diagnosed or new diagnosis or inception) adj5 diabetes).mp. [mp=title, abstract, heading word, drug 
trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading] 
4 1 or 2 or 3 
5 exp glycosylated hemoglobin/ 
6 exp glucose blood level/ 
7 exp hypoglycemia/ 
8 exp hyperglycemia/ 
9 ((early intensive or tight or glyc?emic or glucose or diabetes or strict) adj2 control).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading] 
10 (insulin adj2 (use* or injection* or dose* or pump*)).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading] 
11 (glycosylat* or HbA1c or A1c or H?emoglobin A or HbA?1c).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading] 
12 ((intensive or conventional or standard or regular or optimi?ed or usual or routine) adj2 (care or treatment or therapy or intervention or management)).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading] 
13 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 
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14 
diabetic angiopathy/ or diabetic cardiomyopathy/ or diabetic coma/ or diabetic foot/ or diabetic hypertension/ or diabetic ketoacidosis/ or diabetic macular edema/ 
or diabetic nephropathy/ or diabetic neuropathy/ or diabetic obesity/ or diabetic retinopathy/ or impaired glucose tolerance/ or "maternally inherited diabetes and 
deafness"/ or nonketotic diabetic coma/ or wolfram syndrome/ 
15 exp diabetes mellitus/co [Complication] 
16 exp diabetes mellitus/si [Side Effect] 
17 exp insulin resistance/ 
18 exp autoimmune disease/ 
19 exp albuminuria/ 
20 exp kidney disease/ 
21 exp dialysis/ 
22 exp blindness/ 
23 exp cardiovascular disease/ 
24 exp cerebrovascular disease/ 
25 exp blood pressure/ 
26 exp hydroxymethylglutaryl coenzyme A reductase inhibitor/ 
27 exp mortality/ 
28 
(Diabetes complication* or side effects or adverse events or glyc?emia or hyper glyc?emia or hyperglyc?emia or hypo glyc?emia or hypoglyc?emia or ketosis or 
diabetic ketoacidosis or DKA or nonketotic hyperosmolar coma or insulin resistance or autoimmune disease* or urine albumin or microalbuminaria or 
macroalbuminuria or renal disease* or kidney disease* or diabetic nephropathy or nephropathy or dialysis or foot ulcer or amputation or retinopathy or blindness 
or cardiovascular disease* or MI or myocardial infarction* or stroke* or coronary artery disease* or cerebrovascular disease* or peripheral vascular disease* or 
blood pressure or BP or statin* or death or mortality).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword, floating subheading] 
29 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 
30 memory/ 
31 metabolic memory.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading] 
32 30 or 31 
33 4 and 13 and 29 and 32 
 
 
VI.  Medline (via OVID) (Original: 16/12/2014; Updated: 17/02/2017) 
1 exp Diabetes Mellitus, Type 1/ 
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2 
(((DM1 or diabetes mellitus 1 or diabetes mellitus) adj2 type 1) or T1D or T1DM or IDDM).mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique 
identifier, synonyms] 
3 
((type 1 or p?ediatric or child* or young people or youth or young adults or juvenile or insulin dependent or labile or brittle or sudden onset or 
autoimmune or auto immune or non insulin dependent or uncontrolled or newly diagnosed or new diagnosis or inception) adj5 diabetes).mp. 
[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier, synonyms] 
4 1 or 2 or 3 
5 exp Blood Glucose/ 
6 hemoglobins/ or hemoglobin a, glycosylated/ 
7 exp Hypoglycemia/ 
8 exp Hyperglycemia/ 
9 
((early intensive or tight or glyc?emic or glucose or diabetes or strict) adj2 control).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, 
synonyms] 
10 (insulin adj2 (use* or injection* or dose* or pump*)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms] 
11 (glycosylat* or HbA1c or A1c or H?emoglobin A or HbA?1c).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms] 
12 
((intensive or conventional or standard or regular or optimi?ed or usual or routine) adj2 (care or treatment or therapy or intervention or 
management)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier, synonyms] 
13 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 
14 exp Diabetes Complications/ 
15 adverse effects.fs. 
16 complications.fs. 
17 exp Ketosis/ 
18 exp Insulin Resistance/ 
19 exp Autoimmune Diseases/ 
20 exp Albuminuria/ 
21 exp Kidney Diseases/ 
22 exp Dialysis/ 
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23 exp Blindness/ 
24 exp Cardiovascular Diseases/ 
25 exp Cerebrovascular Disorders/ 
26 exp Blood Pressure/ 
27 exp Hydroxymethylglutaryl-CoA Reductase Inhibitors/ 
28 exp Mortality/ 
29 
(Diabetes complications or side effects or adverse events or glycaemia or hyper glycaemia or hypo glycaemia or ketosis or diabetic ketoacidosis or 
DKA or nonketotic hyperosmolar coma or insulin resistance or autoimmune disease or urine albumin or urine albumin creatinine ratio or urine 
albumin excretion or microalbuminuria or macroalbuminuria or renal disease or diabetic nephropathy or nephropathy or dialysis or foot ulcer or 
amputation or retinopathy or blindness or cardiovascular disease or MI or myocardial infarction or stroke or coronary artery disease or 
cerebrovascular disease or peripheral vascular disease or blood pressure or BP or statin or death or mortality).mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept 
word, unique identifier, synonyms] 
30 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 
31 4 and 13 and 30 
32 metabolism.fs. 
33 metabolic memory.mp.  
34 32 or 33 
35 31 and 34 
 
 
Additional File 3: Inclusion and exclusion criteria for review of evidence on effect of early HbA1c levels on glycaemic trends and later complications 
Inclusion Criteria Exclusion Criteria 
- Interventional studies (RCT’s and non-RCT’s) targeting glycaemic control (within 2 
years of diagnosis of T1D) and described an association with health outcomes 
- Non-intervention/observational i.e. cohort and cross sectional (XS) studies that 
quantified the association between early glycaemic control (within 2 years of diagnosis 
of T1D) AND risk of future complications in children and young people aged 0 to 19 
years at baseline  
 
- longitudinal studies with a follow-up of ≥ 5 years from diagnosis  
- Non-human studies 
- Selection of population based on other diseases/co-morbidities  
- Adults aged more than 19 years at baseline. 
- Studies on T2D  
- Quantitative studies not reporting clinical outcomes 
- Quantitative studies that measured glycaemic control but did not describe an 
association with outcome variables  
Additional File 4: Details of data extracted from included studies  
Observational/Non-intervention studies (cross-sectional and longitudinal) 
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- Study id  
- Author  
- Year  
- Country  
- Age Range  
- Average age  
- Sex (Male: Female ratio)  
- Ethnicity  
- Socioeconomic status  
- Design (Cross sectional/longitudinal)  
- Number of participants  
- Sample/recruitment e.g general population representative sample or specialist groups,  
- Exposure  examined  
- Measurement of Exposure  
- Measurement conducted by Level of glycaemic control  
- Setting (home, primary care, secondary care)   
- Outcome (HbA1c levels, complications, HbA1c tracking/metabolic memory - separate row for each outcome 
investigated),  
- Measurement of outcome (objective)   
- Analysis  
- Effect 
- Author email  
- Comments  
 
 
Additional File 5: Quality assessment criteria 
For observational (prospective/retrospective cohort and cross sectional) studies 
Total quality assessment score (maximum of 6) was derived for fulfilment of following criteria: 
 
1) More than 50 participants analysed; 
2) Studies representing general population 
3) Prospective study design 
4) Adjusted/multivariate analysis 
5) Objective measure of outcome 
6) Objective measure of exposure. 
 
 
